Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Am J Hematol. 2019 Jan 24;94(4):475–488. doi: 10.1002/ajh.25397

Figure 4-. Schematic approach for the management of myelodysplastic syndromes with single lineage dysplasia and ring sideroblasts.

Figure 4-

Key- MDS-RS- myelodysplastic syndrome with ring sideroblasts, EPO- erythropoietin, rH- recombinant human, G-CSF- granulocyte colony stimulating factor, ESA- erythropoiesis stimulating agents. * Immunosuppressive therapy could be considered in individuals with hypoplastic bone marrows and a HLA-DR-15 phenotype.